Bentley Pharmaceuticals receives approval to market new 28-capsule presentation of its ulcer product, Belmazol, in Spain.TAMPA, Fla.--(BUSINESS WIRE)--Feb. 24, 1997--Bentley Pharmaceuticals, Inc. (AMEX AMEX See: American Stock Exchange :BNT BNT Bentley Pharmaceuticals, Inc. (stock symbol) BNT Boston Naming Test (psychology) BNT Bermuda National Trust BNT Bulgarian National TV BNT Broadband Network Termination BNT Binary File Transfer ) announced today that it has received approval from the Spanish Ministry of Health to begin marketing in Spain, a new 28-capsule presentation of its lead gastrointestinal product, Belmazol. The company is preparing to launch the product in early April 1997. Sales of Belmazol accounted for approximately $4.5 million of Bentley Pharmaceuticals, Inc.'s revenues in 1996. The new 28-capsule presentation should allow Bentley Pharmaceuticals to accelerate the rate of its market share growth and management expects sales of Belmazol to exceed $6.5 million in 1997. Belmazol, used primarily for hyperacidity hy·per·a·cid·i·ty n. Abnormally high acidity, as of the stomach. hyperacidity excessive acidity. problems related to ulcers and gastroesophageal reflux disease gastroesophageal reflux disease (GERD) Disorder characterized by frequent passage of gastric contents from the stomach back into the esophagus. Symptoms of GERD may include heartburn, coughing, frequent clearing of the throat, and difficulty in swallowing. , is a proton pump inhibitor proton pump inhibitor n. A class of drugs that inhibit gastric acid secretion by interfering with the movement of hydrogen ions across cell membranes and are used mainly to treat peptic ulcers, gastroesophageal reflux disease, and esophagitis. which inhibits the hydrogen/potassium ATPase enzyme system at the secretory surface of gastric parietal cells. Because this enzyme system is regarded as an acid pump within the gastric mucosa, it has been characterized as a gastric acid pump inhibitor in that it blocks the final step of acid production. This compound has been used in combination with antibiotics for the treatment of ulcers when it is suspected that Helicobacter pylori, a bacteria, is the etiologic agent. James R. Murphy, chairman and CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. of Bentley Pharmaceuticals, said, "This accomplishment is particularly significant because Belmazol is not only our highest gross margin product, but it is also our fastest growing product. This is but another example of the creativity of our marketing division in producing a therapeutic packaging unit that cuts packaging costs, increases gross margins, and enhances our market share." By leveraging competitive advantages of relatively low-cost GMP GMP (guanosine monophosphate): see guanine. accredited accredited recognition by an appropriate authority that the performance of a particular institution has satisfied a prestated set of criteria. accredited herds cattle herds which have achieved a low level of reactors to, e.g. manufacturing capability, novel drug-delivery technologies and an international sales-and-marketing presence, Tampa-based Bentley Pharmaceuticals, Inc. is an emerging international pharmaceutical company with a broad and expanding line of improved off-patent drugs that prevent or treat illnesses in the following therapeutic categories -- cardiovascular, gastrointestinal, neurological, and infectious diseases. Safe Harbor Statement under the Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and of 1995: The statements which are not historical facts contained in this press release are forward-looking statements that involve certain risks and uncertainties including but not limited to risks associated with the uncertainty of future financial results, additional financing requirements, development of new products, regulatory approval processes, the impact of competitive products or pricing, unpredictability of patent protection, technological changes, the effect of economic conditions and other uncertainties detailed in the company's filings with the Securities and Exchange Commission. CONTACT: Bentley Pharmaceuticals, Inc. Michael D. Price, Chief Financial Officer 813/286-4401 or Porter, LeVay & Rose, Inc. Michael J. Porter 212/564-4700 or Continental Capital & Equity Corporation Jimmy Holton 407/875-1110 www.insidewallstreet.com |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion